Synovial incorporation of polyacrylamide hydrogel after injection into normal and osteoarthritic animal joints  by Christensen, L. et al.
Osteoarthritis and Cartilage 24 (2016) 1999e2002Brief ReportSynovial incorporation of polyacrylamide hydrogel after injection into
normal and osteoarthritic animal joints
L. Christensen y *, L. Camitz z, K.E. Illigen x, M. Hansen k, R. Sarvaa ¶, P.G. Conaghan #
y Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark
z Camitz Equestrian, Glumsoe, Denmark
x Statens Serum Institut, Copenhagen, Denmark
k Hojgaard Horse Hospital, Fuen, Denmark
¶ Felina Cat Clinic, Copenhagen, Denmark
# Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UKa r t i c l e i n f o
Article history:
Received 11 March 2016




Polyacrylamide hydrogel* Address correspondence and reprint requests to: L
Pathology, Herlev Hospital, Herlev Ringvej 75, 2730 H
E-mail addresses: lise.christensen.01@regionh.dk (
dk (L. Camitz), KEI@ssi.dk (K.E. Illigen), kontakt
(M. Hansen), Dyredoktor@hotmail.com (R. Sarva
(P.G. Conaghan).
http://dx.doi.org/10.1016/j.joca.2016.07.007
1063-4584/© 2016 The Author(s). Published by Elsevi
license (http://creativecommons.org/licenses/by-nc-ns u m m a r y
Objective: Polyacrylamide hydrogel (PAAG) is a non-toxic, non-degradable synthetic product, used for
years in the augmentation of soft tissues. Preliminary results in animals and humans have suggested
long-lasting beneﬁcial effects on symptoms of osteoarthritis (OA). The aim of this histopathological study
was to investigate whether intra-articular injection of PAAG is integrated into synovial tissue in normal
and OA animal joints, and if this integration is sustained.
Methods: (A) A prospective, controlled, longitudinal study of normal knee joints injected with PAAG was
performed in 10 rabbits, following the animals up to 1 year, and (B) a post mortem examination was
carried out up to 2 years post-injection on 18 horse joints which had previously been treated with 1e2
injections of 2 ml PAAG for clinically and radiologically diagnosed OA.
Results: Integration of the injected gel was evident at day 10 in the rabbit and by day 14 in the horse,
with proliferation and invasion of synovial cells into the gel. By day 90 in rabbit joints and day 30 in horse
joints, the gel had formed a sub-synovial layer, which was traversed by thin strands of connective tissue
with vessels and covered by a synovial lining facing the joint cavity. This histological appearance per-
sisted up to 2 years post-injection in horse joints.
Conclusion: Intra-articular injection of PAAG results in a stable, long-lasting sub-synovial layer of gel
traversed with thin strands of connective tissue. Further studies to explore potential effects on synovial
inﬂammation and pain are warranted.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Osteoarthritis (OA) represents a major health problem com-
pounded by aging and increasingly obese populations and is the
fasting growing cause of global disability1. Current treatments are
focused on reducing symptoms, and there are few effective thera-
pies. Most people with OA have persistent pain despite use of all





er Ltd on behalf of Osteoarthritis R
d/4.0/).associated with signiﬁcant toxicities and contra-indications, and
their use is restricted across populations1,2. There is therefore a
major need to develop new analgesic therapies for OA.
Polyacrylamide hydrogel (PAAG) (Contura International A/S,
Soborg, Denmark) is a synthetic, non-degradable hydrogel, which is
biocompatible and non-toxic3 with water exchanging abilities4. The
hydrogel has been used for years in the augmentation of soft tissues
such as skin and bladder neck5e9, and histopathological studies of
soft subcutaneous tissues from mice3, rats5, rabbits6, pigs10 and
humans11 have shown that it supports cellular growth and inte-
gration, and possesses a permanent and stable augmentation effect
due to the constant molecular water exchange with its host tissue4.
PAAG is also known for its ability to allow in-growth of host
tissue cells in vivo. The tissue integration begins immediately after
gel injection as a sort of foreign body reaction to the PAAG. Hostesearch Society International. This is an open access article under the CC BY-NC-ND
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and then invade it. In the process these cells are gradually trans-
formed into ﬁbroblasts and endothelial cells, which eventually
form a thin vessel-bearing ﬁbrous network inside the gel10.
In a preliminary study, PAAG demonstrated analgesic beneﬁts in
equine OA joints up to 2 years post injection12. In order to under-
stand any potential mechanism of action of PAAG, the ﬁrst step
would be to demonstrate if the gel was retained over the duration
of purported beneﬁt, and where the gel would be located following
injection (joint cavity or tissues). The main purpose of this histo-
pathological study was therefore to investigate the fate of the gel
following injection, and the secondary aims were to determine the
duration of retention and possible tissue distribution at different
times after intra-articular injection of PAAG in normal and OA an-
imal joints.
Methods
Two animal joint types were examined. Firstly, we conducted a
prospective, longitudinal, controlled study on normal knee joints in
rabbits, and secondly, a post mortem examinationwas made on OA
horse joints which had been treated with PAAG at different times
prior to death. The PAAG used in all these cases was Aquamid
Reconstruction® (Contura International A/S, Soeborg, Denmark).
Ethical approval was obtained from the Danish Animal Welfare
Organization (dyreforsøgstilsynet, reference J.nr. 2010/561-1774).
Prospective comparative study in normal rabbit joints
A total of 10 two-year old New Zealand white rabbits were used.
The ﬁrst four received injections in the right knee with 2.5% PAAG
and in the left knee saline as control. The remaining six rabbits also
received PAAG injections in the right knee but in the left knee they
received hyaluronic acid gel (HAG, Durolane 20 mg/ml, Galderma,
Switzerland) as a control. The volume of injected PAAG, saline or
HAG was 0.3 ml per knee. This was administered after having
removed a few drops of joint ﬂuid to ensure correct position of the
injection needle. The rabbits were observed daily for well-being
and their weight was measured once a week and they were kept
under standard conditions in pairs. The ﬁrst four rabbits (saline
control group) were sacriﬁced after 10 days. The remaining six
rabbits were sacriﬁced, two at a time, after 3, 6 and 12 months. For
all 10 rabbits both knee joints were removed and inspected
macroscopically. All synovial, cartilage, tendon and fatty tissue of
the joint was removed and processed for histopathological exam-
ination using H&E and van Gieson/Alcian blue stains as tissue
markers.
A study of osteoarthritic joints in the horse
This study included seven horses (age 5e13 years, median 10
years) presenting a total of 13 joints with veterinarian-diagnosed
OA that had been treated with PAAG. Five joints without OA
served as controls. The horses were part of a large prospective
clinical study carried out at three different equine centers, where
1e4 (mean 2)ml of PAAG had been injected per joint andwhere the
effect of the treatment was followed postoperatively for up to 2
years12. Histopathological examinationwas carried out on leg joints
from horses having died during that period. Treatment with PAAG
had been performed from 7 days to 2 years previously. All horses
had been euthanized for causes unrelated to the PAAG treatment.
After dissection and macroscopic inspection of the joints, all sy-
novial tissue representing the inner capsule was routinely ﬁxed,
parafﬁn embedded and stained for light microscopy. Samples from
the cartilage were also examined (two from each joint).Results
Rabbit study
The rabbits with normal joints were all healthy at injection and
remained so during the study with no change in joint movement
(e.g., activity restriction or limping) at any time.
On gross inspection there were no differences other than two
cases of slight capsule hemorrhage at injection site. Upon opening
the joint cavity, the synovial ﬂuid was more viscous, and the inner
synovial lining appeared slightly thickened on the PAAG-treated
side as compared to the saline-treated side at day 10. No macro-
scopic differences could be discerned between PAAG and HAG
treated joints at any time point.
Light microscopy on the PAAG treated side at day 10 showed a
synovial lining layer which was 5e10-fold thicker than on the sa-
line injected side, due to the gel containing proliferating synovial
cells [Fig. 1(a) and (b)].
At 3, 6 and 12 months the synovial layer was still up to 10-times
thickened on the PAAG treated side [Fig. 1(c)], and the synovial
lining was present on top of the gel facing the cavity [Fig. 1(c)]. By
now only scattered synovial cells were seen inside the gel inter-
mixed with a ﬁne ﬁbrous network. PAAGwas no longer seenwithin
the cavity, but on the HAG treated side aminimal amount of a dense
homogenous blue material thought to be a remnant trace of Dur-
olane was seen at 3 months in one of the synovial foldings
[Fig. 1(d)]. This was not seen at 6 and 12 months.
Horse study
Macroscopic ﬁndings
Cofﬁn, fetlock and knee joints had been treated with PAAG.
Three untreated cofﬁn joints and two fetlock joints served as con-
trols. Upon opening the joint cavity, various grades of osteophyte
formation and/or cartilage defect(s) could only be seen in three of
the ﬁve treated fetlock joints. The PAAG appeared as a thick,
smooth, glistening, yellow substance or in the cofﬁn joint as small
clear deposits along the inner part of the anterior longitudinal
tendon facing the cavity. Free PAAG inside the cavity could not be
discerned from joint ﬂuid on naked eye inspection.
Light microscopy ﬁndings
In the short term, 1 and 2 weeks post treatment, the PAAG
appeared as an inner layer within the synovial lining intermixed
with proliferating synovial cells, similar to the histology seen in the
rabbit model. At 1 month the synovial cells had apparently relo-
cated towards the surface, and at 3 months a distinct layer of sy-
novial cells had formed on top of the integrated PAAG [Fig. 2(a)].
The same patternwas found at 8months and at 24months [Fig. 2(c)
and (d)]. In general, there was no reduction in membrane thickness
of the integrated gel, and at higher magniﬁcation, it could be seen
by H&Emorphology that the PAAG hadmaterialized itself as a thick
integrated zone with at ﬁrst scattered mononuclear inﬂammatory
cells, possibly synovial cells [Fig. 2(a)], and later with a ﬁne ﬁbrous
network and very few of these inﬂammatory cells [Fig. 2(d)].
Discussion
This histopathological study investigating the location and
retention of PAAG in joints with and without OA has revealed that
PAAG appears to form a sub-lining layer. All examined joints from
both species showed the same PAAG integration into the inner layer
of the synovium and the re-location of the synovial cells on the
surface. Furthermore, we found that integrated PAAG was
Fig. 1. Rabbit normal knee joint injected with PAAG and saline after 10 days (a, b) and with PAAG and HAG after 30 days (c, d). At 10 days the blue gel was still lying in the cavity,
where it was dominated by proliferating synovial cells (a, thin arrow). Normal synovium was seen on the saline injected side (b, thin arrow). At 3 months the synovial lining was
intact (c) on top of a layer of blue PAAG containing scattered chronic inﬂammatory cells intermixed with a ﬁne ﬁbrous network (fat arrows). There was no PAAG in the cavity, but
traces of a HAG-like material were seen within the cavity in a few of the synovial folds (d, fat arrows). HE 400 (a, b), HE 200 (c, d).
Fig. 2. Horse fetlock joint treated with PAAG for OA after 3 months (a) and after 24 months (c, d). Non-treated fetlock synovial control tissue is shown in b. The synovial surface
lining is marked with arrows. The ﬁne ﬁbrous network with blood vessels inside the gel at 24 months is circled in d. HE 200 (a, b), HE 60 (c), and van Gieson/Alcian blue 150 (d).
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thickness.
The main differences between the integration of PAAG in
previous tissues and the synovial membrane of the present study is
that the previous studies were not associated with any luminal
surfaces and the gel containedmacrophages and giant cells up until14 months post injection10. The current study uniquely demon-
strated the formation of a novel synovial lining layer after inte-
gration of the PAAG, and no giant cells at any time [Figs.1(a), (c) and
2(a), (c), (d)].
Analgesic beneﬁts for PAAG have been reported in an observa-
tional study in the horse, where one treatment of 2 ml PAAG in
L. Christensen et al. / Osteoarthritis and Cartilage 24 (2016) 1999e20022002fetlock or carpus joints was found to have a signiﬁcant effect on
lameness and effusion during the ﬁrst month post treatment, after
which this effect increased progressively until 6 months, and then
stabilized up until 24 months12. Recently an observational pilot
study of 60 human knees with OA, which were treated with non-
degradable PAAG, showed promising results for pain reduction13.
It is interesting to speculate on potential mechanisms by which
PAAG may produce an analgesic effect, and the effects of the sub-
lining layer of PAAG are not clear from this work. There may be
changes to synovial cell composition or cytokine production, and/
or mechanical properties of the synovium. This will require further
investigation, as this study has several limitations including a
limited number of experimental animals, different types of horse
joints, variations in PAAG doses and different time periods of follow
up.
In conclusion, intra-articular PAAG is present in joint synovium
and persists over a time course consistent with reported analgesic
beneﬁts in observational animal and human studies. In parallel
with ongoing clinical studies of efﬁcacy, further studies are needed
to explain its potential mechanism of action.Disclosures
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